Type 2 Myocardial Infarction: The Next Frontier - 22/05/14
Doi : 10.1016/j.amjmed.2014.02.027
Yader Sandoval, MD a, Stephen W. Smith, MD, MD b, Fred S. Apple, PhD c
a Division of Cardiology, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minn
b Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minn
c Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minn
Il testo completo di questo articolo è disponibile in PDF.
| Funding: None. |
|
| Conflict of Interest: FSA is a consultant to or has an advisory role for T2 Biosystems and Instrumentation Laboratory; and has received honoraria from Abbott Laboratories and research funding, without salary, from the majority of manufacturers marketing cardiac troponin assays. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
© 2014
Elsevier Inc. Tutti i diritti riservati.
Vol 127 - N° 6
P. e19 - giugno 2014 Ritorno al numero
Articolo precedente
- The Reply
- James J. DiNicolantonio, Sean C. Lucan, Carl J. Lavie, James H. O'Keefe
- Is Uric Acid an Underdiagnosed Mediator of Adverse Outcome in Metabolically Healthy Overweight/Obese Individuals?
- Mehdi A. Fini, Richard M. Wright, Kurt R. Stenmark, Stephen R. Daniels, Richard J. Johnson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?